share_log

Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025

Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025

Nutriband公司第三季度季度报告突破性地显示,营业收入同比增长50.94%,并取得了AVERSA芬太尼在2025年递交NDA的战略进展。
GlobeNewswire ·  2024/12/04 22:00

ORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today reported its financial results for the third quarter ended October 31, 2024. The Company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, AVERSA Fentanyl, with an NDA submission targeted for first half of 2025.

佛罗里达州奥兰多,2024年12月4日(环球新闻专线)——Nutriband Inc.(纳斯达克股票代码:NTRB)(纳斯达克股票代码:NTRBW)今天公布了截至2024年10月31日的第三季度财务业绩。该公司报告称,季度末现金状况良好,这增强了其推进其主要产品AVERSA Fentanyl开发的能力,并计划于2025年上半年提交保密协议。

Nutriband is continuing to expand its kinesiology tape contract manufacturing services through its Pocono Pharma subsidiary, with a focus on penetration pricing to gain a foothold with some of the industry's largest brands. The Company produced a record third quarter reporting revenue of $645,796 USD, up 50.94% YOY. Pocono manufactured products continue to roll out into prominent retail locations nationwide, including Target, Walmart, Walgreens and CVS.

Nutriband将继续通过其Pocono Pharma子公司扩大其运动学胶带合同制造服务,重点是渗透定价,以便在该行业的一些最大品牌中站稳脚跟。该公司第三季度创下了创纪录的收入645,796美元,同比增长50.94%。波科诺制成品继续在全国主要零售场所推出,包括塔吉特、沃尔玛、沃尔格林和CVS。

Progress continues on the development of AVERSA Fentanyl, with the Company maintaining its goal of submitting an NDA to the FDA in the first half of 2025. Nutriband recently updated shareholders on its development pathway, emphasizing that the NDA will primarily rely on data from a single phase 1 Human Abuse Potential study. Importantly, no Phase 2 or Phase 3 clinical trials will be required before to submission.

AVERSA芬太尼的开发继续取得进展,该公司维持了在2025年上半年向美国食品药品管理局提交保密协议的目标。Nutriband最近向股东通报了其发展路径的最新情况,强调保密协议将主要依赖于单一阶段的人类滥用潜力研究的数据。重要的是,在提交之前不需要进行2期或3期临床试验。

If approved, AVERSA Fentanyl could become the first and only abuse-deterrent transdermal patch available globally. AVERSA Fentanyl is estimated to have the potential to reach peak annual sales of $80-$200 million, according to a market analysis report from Health Advances.

如果获得批准,AVERSA 芬太尼可能成为全球第一个也是唯一的抗滥用透皮贴剂。根据Health Advances的市场分析报告,估计AVERSA芬太尼有可能达到8000万至2亿美元的峰值年销售额。

AVERSA Buprenorphine, which is the company's second application for AVERSA, is projected to reach peak annual sales of up to $130 million.

AVERSA丁丙诺啡是该公司第二次申请AVERSA,预计年销售额将达到高达1.3亿美元的峰值。

As of October 31, 2024, Nutriband's cash reserves stand at $5.7 million, supporting the Company's ongoing development and commercialization efforts for AVERSA Fentanyl. The Company's total assets are valued at $12.55 million, with stockholders' equity amounting to $11.23 million.

截至2024年10月31日,Nutriband的现金储备为570万美元,为公司对AVERSA芬太尼的持续开发和商业化工作提供了支持。该公司的总资产价值为1,255万美元,股东权益为1,123万美元。

About Nutriband Inc.

关于 Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA abuse-deterrent technology. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

我们主要从事透皮药物产品组合的开发。我们正在开发的主要产品是含有我们的 AVERSA 滥用威慑技术的芬太尼贴剂。AVERSA技术可以集成到任何透皮贴剂中,以防止滥用、滥用、转移和意外接触可能滥用的药物。

The Company's website is . Any material contained in or derived from the Company's websites or any other website is not part of this press release.

该公司的网站是。本公司网站或任何其他网站中包含或衍生的任何材料均不属于本新闻稿的一部分。

Forward-Looking Statements

前瞻性陈述

Certain statements contained in this press release, including, without limitation, statements containing the words ''believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended January 31, 2024, filed May 1, 2024, the Forms 10-Q's filed subsequent to the Form 10-K in 2024, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

本新闻稿中包含的某些声明,包括但不限于包含 “相信”、“预期”、“期望” 等词语的陈述以及类似含义的词语,构成1995年《私人证券诉讼改革法》所指的 “前瞻性陈述”。此类前瞻性陈述涉及已知和未知的风险和不确定性。由于多种因素,公司的实际业绩可能与其前瞻性陈述中的预期存在重大差异,包括公司开发其拟议的滥用威慑性芬太尼透皮系统和其他拟议产品的能力、为其滥用技术获得专利保护的能力、获得开发产品和进行必要临床测试所需的融资的能力、获得联邦食品药品监督管理局批准以销售任何产品的能力它可能开发的产品在美国并获得在其他国家(包括欧洲国家)销售任何产品所必需的任何其他监管批准;其销售其可能开发的任何产品的能力;创造、维持、管理和预测其增长的能力;吸引和留住关键人员的能力;公司业务战略或发展计划的变化;竞争;业务中断;负面宣传以及国际、国家和地方总体经济和市场状况以及通常与资本不足相关的风险化发展中公司,以及该公司于2024年5月1日提交的S-1表格、截至2024年1月31日止年度的10-k表格、继2024年10-k表格之后于2024年提交的10-Q表以及公司向美国证券交易委员会提交的其他文件中 “风险因素” 和 “管理层对财务状况和经营业绩的讨论和分析” 中包含的风险。除非适用法律要求,否则我们没有义务修改或更新任何前瞻性陈述以反映本声明发布之日之后可能发生的任何事件或情况。

For more information, contact:

欲了解更多信息,请联系:

RedChip Companies, Inc.
Email: NTRB@Redchip.com
Phone: 1-407-644-4256
Address:
431 E Horatio Ave, Suite #100
Maitland, FL 32751

RedChip 公司有限公司
电子邮件:NTRB@Redchip.com
电话:1-407-644-4256
地址:
E Horatio Ave 431 号,套房 #100
佛罗里达州梅特兰 32751

Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com

Nutriband Inc.
电话:407-377-6695
电子邮件:info@nutriband.com


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发